Sign in
Taking people in United StatesPhase 2/3

Stem cells from umbilical cord lining for dermatomyositis and polymyositis

Tests umbilical cord stem cells against placebo in adults with dermatomyositis or polymyositis.

Key facts

Who runs it
Restem, LLC.
Where
Gainesville and Miami, United StatesSee the 2 sites
Trial code
Registry title
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Status
Recruiting
Phase
Phase 2/3
People taking part
40 people, planned
Started
6 Jan 2026
Expected to end
Aug 2029
Type of study
Interventional, 2 groups
Treatments tested
  • ULSC (1.5 x 10^8 cells/dose)
  • Placebo (no cells)
Record updated
27 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active dermatomyositis or polymyositis (idiopathic inflammatory myositis, a muscle inflammation disease). They are already on standard treatment. Each person gets both ULSC stem cells and a placebo.

Age
18 years and older
Sex
All sexes
Disease stage
Diagnosis of IIM by the 2017 EULAR/ACR criteria, score of ≥ 5.5 (≥ 6.7 with muscle biopsy). The disease must be active, shown by raised CK or Aldolase (more than 1.5 x the upper limit of normal), MRI, EMG or muscle biopsy within 12 weeks. People need muscle weakness (MMT-8 score ≤142/150) or active skin signs (CDASI score ≥ 7). Oxygen level SpO2 ≥ 94% on room air and LVEF ≥ 30% are required.
Earlier treatment
People must be on one or more immunosuppressants, or at least 5 mg prednisone (or equivalent), for their myositis. Immunosuppressant and hydroxychloroquine doses must be stable for at least 12 weeks. Steroid doses must be stable for at least 4 weeks, at most 25 mg/day prednisone. People cannot have started rituximab within 12 weeks before joining.
Biomarker or test result
A positive myositis-associated antibody, or tests done to rule out other diseases that look similar. Tests for HIV, hepatitis B and hepatitis C must be negative.

Main reasons for not taking part

  • Inclusion body myositis, juvenile DM or PM, or myositis overlapping with another autoimmune disease (Sjogren's syndrome allowed)
  • Cancer linked to myositis, or active cancer or cancer within the past 2 years
  • Pregnant or breastfeeding
  • Organ transplant recipient
  • HIV, active hepatitis C, or current or past hepatitis B

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Participants will be ≥18 years old
  • Diagnosis of idiopathic inflammatory myositis (IIM) based on 2017 EULAR/ACR Classification Criteria for adult IIM, corresponding to a score of ≥ 5.5 (≥ 6.7 with muscle biopsy)
  • Active disease as defined by any one of the following test results:; Elevated Creatine Kinase (CK) or Aldolase (more than 1.5 x the upper limit of normal) at screening, OR; MRI positive for active, muscle inflammation within 12 weeks prior to screening, OR; EMG read as active myositis within 12 weeks prior to screening, OR; muscle biopsy obtained within 12 weeks of the screening showing active inflammatory disease
  • Muscle weakness or active cutaneous manifestations of dermatomyositis assessed at Screening and documented with either of the following scores:; Bilateral MMT-8 score of ≤142/150, OR; CDASI Total Activity score of ≥ 7
  • Participants must be receiving standard of care treatment with one or more immunosuppressants or at least 5 mg prednisone (or corticosteroid equivalent); Immunosuppressive doses should be stable for at least 12 weeks prior to enrollment. Participants must remain on stable immunosuppressive therapy for the duration of the trial unless discontinuation is warranted due to toxicity or another clinical reason; Hydroxychloroquine (HCQ) doses should be stable for at least 12 weeks prior to enrollment; Steroid doses should be stable for at least 4 weeks prior to enrollment. At screening and enrollment, maximum dose allowed is 25 mg/day prednisone (or corticosteroid equivalent); Allowed immunosuppressants include: methotrexate, azathioprine, mycophenolate, cyclosporine, IVIG, and others to be evaluated at the discretion of the investigator
  • Participants will either be:; positive for a myositis-associated antibody, OR; will have undergone evaluation to exclude mimics, as deemed appropriate by the Investigator; Note: The minimum workup to be performed on all prospective participants to exclude mimics is as standardly followed, which may include:; Medical history and physical exam to determine the clinical course and progression of symptoms, the distribution of weakness, and the absence of features of myelopathy, neuropathy, neuromuscular disease, myotonic dystrophy, and congenital myopathy; Elevated Creatine Kinase (CK) or Aldolase levels in blood; Electromyography (EMG) and/or MRI of clinically affected 99+proximal muscle group; Myositis-specific and myositis-associated autoantibodies in blood; Muscle biopsy with characteristic features of IIM and excluding features of muscular dystrophy, metabolic myopathies, drug-induce myopathy, inclusion body myopathy, and necrotizing myopathy; Blood tests for exclusion of HIV, Hepatitis B (HBV), and Hepatitis C (HCV). [Screening tests are done for HIV ELISA, HBs Ag, HBc Ab, and HCV Ab with reflex for HCV RNA (PCR) for exclusion criteria.]
  • Adequate pulmonary function, defined as saturated oxygen (SpO2 ≥ 94%) on room air
  • Left ventricular ejection fraction (LVEF) ≥ 30% as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 8 weeks prior to Screening
  • Participants must have the ability to comply with the requirements of the study
  • All participants of reproductive age/capacity will be required to use adequate contraception, defined as at least one form of a highly effective contraceptive (i.e., condoms, hormonal birth control, IUD), with any partners during the study period and for at least three months beyond the study period, for safety
  • Participant will have the ability to understand and provide written informed consent

Who cannot take part

  • Use of other biologic or investigational drug within 6 half-lives for the agent
  • Patients with predominant muscle atrophy secondary to uncontrolled or chronic DM or PM, based on clinical, biochemical, and/or radiologic assessment, despite previous optimized treatment
  • Concomitant severe cardiac, pulmonary disease, active infection, or other conditions that preclude assessment of safety and efficacy of the study product
  • Anticipated need for surgery during the trial period
  • Recipient of an organ transplant
  • Active cancer or prior diagnosis of cancer within the past 2 years, except non-melanoma skin cancer and carcinoma in situ of cervix Potential participants diagnosed with IIM <3 years before screening will have mandatory evaluation for cancer
  • Participants with current or prior hepatitis B infection that could be at risk for reactivation. [For eligibility, screening test results must be HBsAg (DNA) negative and anti-HBc (core antibody total) negative).]
  • A diagnosis of inclusion body myositis, juvenile DM or PM, myositis in the context of significant autoimmune rheumatologic disease
  • Diagnosis of IIM as part of an overlap syndrome (except overlap with Sjogren's syndrome)
  • Diagnosis of myositis-associated interstitial lung disease or cardiac involvement sufficient to limit participation in the trial in the discretion of the PI
  • Cancer associated with myositis
  • Hypersensitivity to study product components including history of hypersensitivity to dimethyl sulfoxide (DMSO)
  • A history of prevalent noncompliance with medical therapy
  • Severe impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min)
  • Participant with HIV or active Hepatitis C. [For eligibility, the following screening tests must have negative or non-reactive results: HIV ELISA, HCV Ab with reflex for HCV RNA (PCR); if HCV Ab test is positive, exclude if HCV RNA (PCR) is positive.]
  • Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition
  • Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up
  • Neutropenia [absolute neutrophil count <1,800/mm\^3 (or <1,000/mm\^3 in African-American participants)]
  • The presence of any of the following criteria excludes a participant from study enrollment:
  • Initiation of Rituxan (rituximab) treatment within 12 weeks of randomization. If participant is already on Rituxan, they must remain on a stable dose throughout the trial
  • End-stage IIM with irreversible muscle involvement seen on biopsy
  • Non-immune myopathies
  • Pregnant or lactating participants
  • Recent or planned use of vaccination with live attenuated viruses

Where in United States

  • Malcom Randall North Florida/South Georgia VA Medical CenterGainesville, United StatesContact: Sarah B LongTaking people
  • Bioresearch PartnerMiami, United StatesContact: Sarah B LongTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about how an umbilical cord lining-derived stem cell (ULSC) product performs when treating Dermatomyositis/Polymyositis (DM/PM), also known as idiopathic inflammatory myopathy (IIM) in adults. It will assess safety and efficacy in relieving symptoms of DM/PM with ULSC administered in three intravenous (IV) doses of 150 million cells per dose.

Read full original descriptionShow less

The main questions that this study plans to answer are:

* Is ULSC as safe as placebo (a look-alike saline without cells) in repeated IV infusion? * Does ULSC improve symptoms of DM/PM after three doses? Researchers will compare ULSC to placebo and evaluate changes from baseline (before first dose) to after each dose and after all three doses are completed per treatment study period. * For participants undergoing steroid (e.g., prednisone) therapy for DM/PM, does ULSC allow their steroid dose to be reduced? Does ULSC reduce need for rescue therapy?

Participants will have been diagnosed with either DM or PM:

* Diagnosed according to the EULAR/ACR 2017 Classification Criteria for idiopathic inflammatory myositis (IIM), which includes DM and PM. * Positive for myositis-associated antibody or undergone evaluation to exclude mimics.

Participants in this study will:

* Participate for total of 25 months with 15 in-person clinic visits and 8 virtual visits on phone or video call. * Receive both ULSC and placebo for a total of 6 IV infusions (260 mL) 3 months apart. * Receive 3 doses of ULSC and 3 doses placebo in either of two sequences, as assigned: ULSC first and placebo second, or placebo first and ULSC second. * If undergoing steroid therapy, will have steroid dose taper prescribing lower doses starting two weeks after the second infusion. * Return for follow-up visits after each dose and up to 12 months after final dose. * Have follow-ups including self-reported questionnaires, physical exam, muscle strength and endurance tests, blood tests, pulmonary function tests, and other assessments.

The 2 groups in the trial

  • Cohort 1: ULSC first; Placebo secondTreatment being tested

    Cohort 1 will receive 1.5 x 10\^8 ULSC per dose through IV infusion on Day 0, Month 3, and Month 6 (total of three doses). One month after the third dose, Cohort 1 will cross-over to receive Placebo IV infusion on Month 7, Month 10, and Month 13.

    Treatment: ULSC (1.5 x 10^8 cells/dose) and Placebo (no cells)

  • Cohort 2: Placebo first; ULSC secondTreatment being tested

    Cohort 2 will receive Placebo IV infusion on Day 0, Month 3, and Month 6 (total of three Placebo infusions). One month after the third dose, Cohort 2 will cross-over to receive 1.5 x 10\^8 ULSC per dose through IV infusion on Month 7, Month 10, and Month 13.

    Treatment: ULSC (1.5 x 10^8 cells/dose) and Placebo (no cells)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2-Phase 3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess the Safety and Efficacy of Allogeneic ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM)
Plain-language title
Stem cells from umbilical cord lining for dermatomyositis and polymyositisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 April 2026
Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) (NCT07160205) – Frontlight Research